NCT05375994 - Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 24, 2025

Study Completion Date

January 1, 2026

Conditions

Non Small Cell Lung CancerKRAS Activating MutationAdvanced CancerMetastatic CancerMalignant Neoplasm of LungMalignant Neoplastic Disease

Interventions

DRUG

avutometinib (VS-6766) and adagrasib

The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion

Trial Locations (8)

Memorial Sloan Kettering Cancer Center, New York

Virginia Cancer Specialists, NEXT Oncology, Fairfax

Mayo Clinic Cancer Center, Jacksonville

Medical College Wisconsin, Milwaukee

Mayo Clinic Cancer Center, Rochester

University of Colorado Hospital Anschutz Cancer Pavllion, Aurora

UCSF Thoracic Oncology, San Francisco

University of North Carolina at Chapel Hill, Chapel Hill